Bristol-Myers Squibb Company (BMY): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Bristol-Myers Squibb Company ( BMY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.1%. By the end of trading, Bristol-Myers Squibb Company rose $0.56 (1.4%) to $40.49 on average volume. Throughout the day, 7,651,659 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9,039,200 shares. The stock ranged in a price between $39.94-$40.49 after having opened the day at $40.06 as compared to the previous trading day's close of $39.93. Other companies within the Health Care sector that increased today were: Unilife Corporation ( UNIS), up 62.2%, Vermillion ( VRML), up 24.7%, Warner Chilcott ( WCRX), up 20.0% and Providence Service Corporation ( PRSC), up 15.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $65.2 billion and is part of the drugs industry. The company has a P/E ratio of 44.6, above the S&P 500 P/E ratio of 17.7. Shares are up 21.8% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 13 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Pain Therapeutics ( PTIE), down 49.6%, Durect Corporation ( DRRX), down 34.0%, Affymax ( AFFY), down 24.9% and LipoScience ( LPDX), down 23.2% , were all laggards within the health care sector with CareFusion ( CFN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact